Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.

ABSTRACT:

Background

A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly vaccinated populations has aroused concerns about the effectiveness of current vaccines.

Methods

We used a test-negative case-control design to estimate vaccine effectiveness against symptomatic disease caused by the omicron and delta (B.1.617.2) variants in England. Vaccine effectiveness was calculated after primary immunization with two doses of BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca), or mRNA-1273 (Moderna) vaccine and after a booster dose of BNT162b2, ChAdOx1 nCoV-19, or mRNA-1273.

Results

Between November 27, 2021, and January 12, 2022, a total of 886,774 eligible persons inf

SUBMITTER: Andrews N 

PROVIDER: S-EPMC8908811 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature